Role of FGF19 in regulating mitochondrial dynamics and macrophage polarization through FGFR4/AMPKα-p38/MAPK Axis in bleomycin-induced pulmonary fibrosis
Yang Li , Hong Zhang , Bing Li , Xin Yi , Xinri Zhang
{"title":"Role of FGF19 in regulating mitochondrial dynamics and macrophage polarization through FGFR4/AMPKα-p38/MAPK Axis in bleomycin-induced pulmonary fibrosis","authors":"Yang Li , Hong Zhang , Bing Li , Xin Yi , Xinri Zhang","doi":"10.1016/j.cyto.2025.156978","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>In the bleomycin (BLM)-induced pulmonary fibrosis model, macrophage polarization and mitochondrial dynamic imbalance are critical drivers of fibrogenesis. Although fibroblast growth factor 19 (FGF19) has been reported to alleviate fibrosis, its mechanism of regulating mitochondrial dynamics and macrophage polarization through the FGFR4/AMPKα-p38/MAPK axis remains unclear.</div></div><div><h3>Objective</h3><div>To investigate whether FGF19 mitigates alveolar epithelial injury and pulmonary fibrosis by restoring mitochondrial fusion/fission balance and modulating macrophage phenotype switching.</div></div><div><h3>Methods</h3><div>A BLM-induced C57BL/6 mouse fibrosis model was employed, with lung-specific FGF19 overexpression via lentivirus. An in vitro RAW264.7 macrophage-alveolar epithelial cell coculture system was used to assess mitochondrial morphology (transmission electron microscopy), mtDNA content (qPCR), protein expression (MFN1/2, Drp1-pSer616; Western blot), and macrophage polarization (flow cytometry). Pharmacological inhibition (SB203580, a p38/MAPK inhibitor) and MFN1/MFN2 siRNA knockdown were applied to validate pathway specificity.</div></div><div><h3>Results</h3><div>(1) FGF19 overexpression significantly attenuated BLM-induced alveolar destruction, collagen deposition, and inflammatory infiltration (H&E, <em>P</em> < 0.01); (2) FGF19 activated the FGFR4/AMPKα-p38/MAPK pathway, upregulated mitochondrial fusion proteins MFN1/2 (<em>P</em> < 0.01), suppressed Drp1 phosphorylation (Ser616)-mediated fission (<em>P</em> < 0.05), and shifted macrophages toward an M2 phenotype (CD206↑, <em>P</em> < 0.01); (3) p38/MAPK inhibition or MFN1/2 knockdown reversed FGF19-driven M2 polarization (P < 0.01); (4) FGF19 reduced alveolar epithelial apoptosis (Annexin V-FITC, P < 0.01) and inflammatory cytokine release (TNF-α, IL-6; ELISA, P < 0.01) by inhibiting M1 polarization.</div></div><div><h3>Conclusion</h3><div>FGF19 alleviates pulmonary fibrosis by restoring mitochondrial dynamics via the FGFR4/AMPKα-p38/MAPK axis, thereby inhibiting M1 macrophage polarization and epithelial injury. These findings highlight FGF19 as a potential therapeutic target for antifibrotic interventions.</div></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"193 ","pages":"Article 156978"},"PeriodicalIF":3.7000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466625001255","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
In the bleomycin (BLM)-induced pulmonary fibrosis model, macrophage polarization and mitochondrial dynamic imbalance are critical drivers of fibrogenesis. Although fibroblast growth factor 19 (FGF19) has been reported to alleviate fibrosis, its mechanism of regulating mitochondrial dynamics and macrophage polarization through the FGFR4/AMPKα-p38/MAPK axis remains unclear.
Objective
To investigate whether FGF19 mitigates alveolar epithelial injury and pulmonary fibrosis by restoring mitochondrial fusion/fission balance and modulating macrophage phenotype switching.
Methods
A BLM-induced C57BL/6 mouse fibrosis model was employed, with lung-specific FGF19 overexpression via lentivirus. An in vitro RAW264.7 macrophage-alveolar epithelial cell coculture system was used to assess mitochondrial morphology (transmission electron microscopy), mtDNA content (qPCR), protein expression (MFN1/2, Drp1-pSer616; Western blot), and macrophage polarization (flow cytometry). Pharmacological inhibition (SB203580, a p38/MAPK inhibitor) and MFN1/MFN2 siRNA knockdown were applied to validate pathway specificity.
Results
(1) FGF19 overexpression significantly attenuated BLM-induced alveolar destruction, collagen deposition, and inflammatory infiltration (H&E, P < 0.01); (2) FGF19 activated the FGFR4/AMPKα-p38/MAPK pathway, upregulated mitochondrial fusion proteins MFN1/2 (P < 0.01), suppressed Drp1 phosphorylation (Ser616)-mediated fission (P < 0.05), and shifted macrophages toward an M2 phenotype (CD206↑, P < 0.01); (3) p38/MAPK inhibition or MFN1/2 knockdown reversed FGF19-driven M2 polarization (P < 0.01); (4) FGF19 reduced alveolar epithelial apoptosis (Annexin V-FITC, P < 0.01) and inflammatory cytokine release (TNF-α, IL-6; ELISA, P < 0.01) by inhibiting M1 polarization.
Conclusion
FGF19 alleviates pulmonary fibrosis by restoring mitochondrial dynamics via the FGFR4/AMPKα-p38/MAPK axis, thereby inhibiting M1 macrophage polarization and epithelial injury. These findings highlight FGF19 as a potential therapeutic target for antifibrotic interventions.
期刊介绍:
The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
* Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors.
We will publish 3 major types of manuscripts:
1) Original manuscripts describing research results.
2) Basic and clinical reviews describing cytokine actions and regulation.
3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.